^
Association details:
| Biomarker: | EGFR C797S |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | BBT-176 (EGFR inhibitor, Tyrosine kinase inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
MA07.09 - BBT-176, a 4th generation EGFR TKI, for Progressed NSCLC after EGFR TKI Therapy: PK, Safety and Efficacy from Phase 1 Study
Published date:
07/12/2022
Excerpt:
Reduction in EGFR mutation allelic frequency was observed in three patients, including non-classical exon 19 deletion and T790M. These changes were correlated with tumor shrinkage in two of the patients. Two patients harboring triple mutations of exon 19 del/T790M/C797S showed radiological improvements in both target and non-target lesions. Continuous daily dosing of BBT-176 was well-tolerated with manageable toxicities.
Trial ID:
